Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET

Company Participants

Alex Braun - Head IR

Daniel O'Connell - President and CEO

Eric Siemers - CMO

Matt Zuga - CFO and CBO

Conference Call Participants

Tom Shrader - BTIG

Judah Frommer - Credit Suisse

Charlie Yang - Bank of America

Operator

Good day. Thank you for standing by. Welcome to the Acumen Pharmaceuticals, Q3 2022 Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers' presentation, there'll be a question-and-answer session [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Alex Braun, Head of Investor Relations. Please go ahead.

Alex Braun

Thank you, Latonya. Good afternoon and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended September 30th, 2022.

With me today are Dan O'Connell, our Chief Executive Officer; Dr. Eric Siemers, our Chief Medical Officer; and Matt Zuga, our Chief Financial Officer and Chief Business Officer.

Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued this afternoon and related slide presentation that we'll discuss today.

Please note that during today's conference call, we may make forward-looking statements within the meaning of the Federal Securities laws, including statements concerning our financial outlook and expected business plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Please see slide two of the accompanying presentation, our press release issued this afternoon, and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements.

We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments. After our prepared remarks, we'll open the call for Q&A.

Now, I'll turn the call over to Dan.

Daniel O'Connell

Thank you, Alex. Good afternoon and thank you for joining our call today. The third quarter was characterized by increased momentum on several fronts for Acumen. The highlights include improved enrollment in the ongoing INTERCEPT-AD trial, Fast-Track designation for ACU193 from the FDA, and publication of our INTERCEPT-AD trial design and anticipated critical development plans for ACU193.